Spotlight -

Drug Development|

Quality Systems

|Videos|May 27, 2023

Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart

Author(s)Chris Spivey

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on the topic of rapid accurate mRNA potency assay possibilities.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

What to Know from the FDA’s End of August Activity

ByZachary Zubulake

August 28th 2026

PharmTech Weekly Roundup—August 28, 2026

BySusan Haigney

August 28th 2026

Strategies to Maximize Stability of Emerging Biologics

August 27th 2026

FDA-approved RASONQUE (daraxonrasib) tablets mark the first broad RAS-targeted therapy for metastatic pancreatic cancer treatment.

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

ByZachary Zubulake

August 26th 2026

Data-driven pharma development: analytics and predictive modelling are reshaping how drug development risks are identified and managed.

Can Predictive Modelling Fix Fragmented Pharma Development Data?

ByZachary Zubulake

August 26th 2026

Trending on Pharmaceutical Technology

3D Printing Revolutionizing Tissue Engineering and Regenerative Medicine in Europe

Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

What to Know from the FDA’s End of August Activity

Rethinking the Path from Spray-Dried Dispersions to Tablets: The Role of Continuous Direct Compression